|
市場調查報告書
博瑞爾(G.Steven Burrill)的生物科技 2008
Biotech 2008 - Life Sciences: A 20/20 Vision to 2020
|
博瑞爾(G.Steven Burrill)的生物科技 2008 是由出版商BURRILL & COMPANY在2008年04月所出版的。
這份英文市場調查報告書價格從美金295起跳。
本報告書內容包括：生物科技產業的動向及未來發展預測、2007年主要企業的財務狀況、對一般醫療・個人化醫療・預防醫 療・健康・農業領域・工業領域・燃料領域等的影響、幹細胞・奈米科技等主要技術開發、相關政策、企業間合約・資本市場動向、主要 地區動向等。內容綱要摘記如下：
第1章 2020年之前的預測
第2章 產業矩陣
- 2007年：提要簡介
- 資本市場
- 財務狀況
- M&A・企業合作
- 規範
- 流動的生物燃料
- 全球生物科作物範圍擴大
- 國際動向
- Burrill公司的預測、等
第3章 醫療
第4章 健康
- 消費者要求的品質體驗
- 健康及預防醫療：醫療產業的焦點名詞
- 健康的高齡化
- 針對肥胖人口市場
- 未來發展預測
第5章 新技術
- 影響醫療領域的技術
- 系統生物學
- 奈米醫療
- NIH的藍圖
- RNA的力量
- 基因治療
- 基因體學
第6章 政治及政策
- FDA Amendments Act
- 環境變化
- 診斷及設備
- 專利
- 全球幹細胞開發
- 亞洲動向
- EU的發展動向
第7章 Agbio（農業生物）
- 基因革命帶來的綠色革命（Green Revolution）變化
- 帶動革新的企業
- 成為主流的基因轉殖學
- 實現技術
- 未來發展預測
第8章 針對產業的生物科技・生物燃料
- 新生物經濟
- 企業的開發成果
- 生物能源
- 未來發展預測
第9章 國際動向
第10章 M&A・企業合作
第11章 金融&資本市場
- 生物科技資金
- 生物科技企業的IPO
- China Connection
- 銷售企業資本
- 發展狀況良好的資本市場、等
第12章 關於Burrill & Company公司
Abstract
2007 Industry Financials, including 12 months of company financial data and
market caps for the US, Europe, Canada, and Asia
Analysis of key activities across industry sectors including healthcare,
personalized, predictive and, preventive medicine, wellness, ag-biotech,
industrial biotechnology and biofuels
- Highlights of the most important recent advances in technology including
stem cells and nanotechnology
- Politics and Policy - with special features on the presidential campaign
and how it is likely to affect the life sciences industry
- Analysis of deal making, the venture capital environment and capital
markets.
- The biotech industry around the world - Canada, Europe, Asia, with special
features on emerging global players such as China, India, Malaysia, Brazil
Table of Contents
Chapter 1: 20/20 Vision to 2020
- Our Vision
- Healthcare
- AgBio
- The Global Scene
- Business Models and Market Cap
Chapter 2: Industry Metrics
- 2007 Snapshot
- The Capital Markets
- Financings
- M&A/Partnering
- Regulatory
- Biofuels in the Melting Pot
- Global Biotech Crop Area Increased
- International
- Burrill' s Predictions for Biotech in 2008
Chapter 3: Healthcare
- Pharma Readies for the Future
- Modest Growth Predicted for Pharmaceutical Market
- Mixed Year for Pharma and Biotech
- Pharma' s Top-Selling Drugs Starting to Peak
- Steady Growth for Biotech Drugs
- Product Approvals
- Selected Major Setbacks in 2007
- Innovation Gap Still Wide
- Healthcare Spending
- Personalized Medicine
- Investors Wowed by Personalized Medicine
- Diagnostics Companies Have a Good Year
- Companion Diagnostics
- Reimbursement is Critical
- Dx Attracts Venture Capital and Suitors
Chapter 4: Wellness
- Consumers Want a Quality Experience
- Big Food Goes Healthy
- Wall Street Performance
- M&A
- Investors Whet Their Appetite
- The International Market
- The Regulatory Arena
- Wellness and Prevention: The New Watchwords of Healthcare
- Nutrigenomics Advances Personalized Nutrition
- Healthy Aging
- Using Beauty Drugs and Foods to Slow the Advance of Time
- Organic Becomes Mainstream
- Targeting Obesity
- Biotech and Pharma Weigh In
- Functional Foods for Weight Control
- Edible Remedies
- Medical Foods and Plant-based Therapies
- Functional Foods
- Probiotics: Focus on Digestive Health
- Supplements
- Looking Ahead
Chapter 5: Emerging Technologies
- Technologies Impacting Healthcare
- Systems Biology
- From Sequences to Systems Biology
- Systems Biology Alters Drug Development
- Nanomedicine
- Nanotubes
- Nanowires
- Nanodiagnostics
- NIH Roadmap 2008
- Human Microbiome Project
- Epigenomics
- The Quest for the $1,000 Genome
- The X PRIZE
- Human Whole-Genome Sequencing
- Illumina Sequences Genome of African Male
- Scientists Create First Synthetic Bacterial Genome
- The Power of RNA
- RNA Interference-Switching Genes Off
- RNA Activation-Switching Genes On
- microRNA-Great Potential in Diagnostics and Treatments
- Gene Therapy
- Genomics: Back on the Radar Screen
Chapter 6: Politics and Policy
- FDA Amendments Act: Higher Fees, Enhanced Safety 118
- PDUFA IV: Booming User Fees
- Trials Registry and Databank
- Conflict of Interest Waivers
- What We Talk About When We Talk About Preemption
- Post-Vioxx: The Need for Improved Drug Safety
- FDAAA and Safety
- Medical Device User Fee and Modernization Act
- Changing Landscape 126
- Diagnostics and Devices 128
- Genomics: The Future of Safety?
- The Genomics and Personalized Medicine Act of 2007
- Personalized Medicine Milestone: Warfarin
- IVDMIAs: FDA Revises Draft Guidance
- MammaPrint: The First
- Report Roundup: Genetics Tests and Nanotech Draw Scrutiny from Federal
Agencies
- Other Device and Diagnostic News
- Patents: Worrisome Patent Changes on the Horizon
- In the Courts
- New USPTO Rules
- Patent Reform Legislation
- Storm Warnings
- Global Stem Cell Developments
- Asia Moves Forward With Stem Cell Research
- Other Stem Cell News
- Asian Trends
- An Overview of EU Developments
Chapter 7: Agbio
- The Gene Revolution Transforms the Green Revolution
- Companies Drive Innovation
- Monsanto: A Long List of Deals
- Syngenta Goes East-To China and Australia
- Dow Goes South-To Latin America
- DuPont: Busy Globally
- Brazil: A Growing Player
- Transgenics Become Mainstream
- Global Metrics
- Countries Move to Develop Own GM Technology
- US Farmers Embrace Transgenics
- Genetic Modification Taking Root in Europe-Slowly
- The Changing Regulatory Landscape
- Enabling Technologies
- RNA Interference as a Pesticide
- Bioremediation
- Enhancing the Nutritional Quality of Food
- Molecular Breeding, A Next-Generation Technology
- Plant-Made Pharmaceuticals Become a Reality
- Transgenic Animals
- Looking Ahead
Chapter 8: Industrial Biotech and Biofuels
- The New Bio-Economy
- International Initiatives
- The United States: the Energy Independence and Security Act of 2007
- Corporate Developments
- Companies Push into the Global Market
- Oil Companies Get Green
- Cleantech Fuels VC Interest
- Alternative Energy Gets US Government Backing
- Bioenergy
- Ethanol
- Cellulosic Ethanol/Biomass
- Biodiesel
- Algae: A Potential Next-Generation Feedstock
- Using Synthetic Biology To Make Designer Microbes
- Microbial Fuel Cells
- Bioplastics
- Integrated Biorefineries
- Biochememicals
- Looking Ahead
Chapter 9: International
- Europe
- Denmark
- Canada
- Australia/New Zealand
- China
- Japan
- Malaysia
- India
Chapter 10: M&A/Partnering
- Activity Down
- Select M&A Transactions
- $5-Billion-plus Deals
- $1-Billion-plus Deals
- Specialty Sector Transactions
- Cancer
- Trends
- Regional M&A
- Partnering
- Deal Activity
- The Top 18
- Regional Alliances
- Analysis of Transactions
- The Outlook to 2020
Chapter 11: Finance & Capital Markets
- No Shortage of Capital for Biotechs
- Positive Year for Biotech IPOs
- China Connection
- Other IPO Winners
- On the Runway
- PIPEs-An Essential Vehicle for Biotech
- Follow-Ons
- Debt
- Venture Capital at Record Levels
- Positive Performance on Capital Markets
- Billion-Dollar Club
- Burrill Mid-Cap Index
- Burrill Small-Cap Index
- Creative Financing and Listing Alternatives
- Euronext
- Biotech Platform
- Looking Ahead
- Industry Financial Data Reconciliation
- Companies Ranked by December 31, 2007 Market Cap
- Companies in Alphabetical Order
Chapter 12: About Burrill & Company
- Burrill & Company
- Venture Capital
- International
- Greater China Group
- India Group
- Japan Group
- Latin America Group
- Malaysia Group
- Middle East Group
- Advisory Boards
- Large Corporate Limited Partners
- Portfolio Companies
- Private Equity
- Merchant Banking
- Media
|
